Evidence map›Paper›PMID 41280003›Full record

ArticlebioRxiv : the preprint server for biology2025

Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV associated gastric cancer.

Sarah Preston-Alp, Yin Wang, Matteo Bergonzoni, Andrew Kossenkov, Samantha Soldan, Lisa Beatrice Caruso, Davide Maestri, Paul M Lieberman, Benjamin Gewurz, Italo Tempera

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Sarah Preston-AlpThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Yin WangDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Matteo BergonzoniThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Andrew KossenkovThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Samantha SoldanThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Lisa Beatrice CarusoThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Davide MaestriThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Paul M LiebermanThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-3935-9921
Benjamin GewurzDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0002-3965-3418
Italo TemperaThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-7893-2914

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial CancersP01CA269043 · NCI · WISTAR INSTITUTE · PI Italo Tempera · 2023 to 2026
$12.0M
Epigenetic Regulation of Epstein-Barr Virus Latency ProgramsR01DE017336 · NIDCR · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 2005 to 2026
$6.5M
B cell determinants of EBV latency (supplement)U01CA275301 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ethel Cesarman, Benjamin Elison Gewurz · 2022 to 2026
$4.0M
Regulation of Viral Chromatin Architecture During EBV LatencyR01AI130209 · NIAID · WISTAR INSTITUTE · PI Italo Tempera · 2018 to 2026
$3.8M
Epstein-Barr virus LMP1 mediated oncogenicityR01CA228700 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2019 to 2026
$3.3M
Drugging EBNA1 to Treat EBV-Associated Cancers - Diversity SupplementR01CA259171 · NCI · WISTAR INSTITUTE · PI MESSICK, TROY E · 2021 to 2025
$3.3M
Regulation of the Epstein-Barr Virus Lytic SwitchR01AI164709 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Benjamin Elison Gewurz · 2021 to 2026
$3.1M
PrEP adherence-concentration thresholds associated with HIV protection among African womenR01AI155086 · NIAID · UNIVERSITY OF WASHINGTON · PI ANDERSON, PETER L., MUGWANYA, KENNETH KIGGUNDU · 2021 to 2024
$3.1M
Regulation of EBV Latency by Purine Metabolism and SignalingR01AI153508 · NIAID · WISTAR INSTITUTE · PI TEMPERA, ITALO · 2021 to 2025
$2.3M
IL-27-producing B cells in the antibody responseR01AI153506 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI XU, ZHENMING · 2021 to 2025
$2.2M
NCI NIH HHS P01 CA269043NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA228700NCI NIH HHS R01 CA259171NCI NIH HHS R50 CA211199NCI NIH HHS T32 CA009171NCI NIH HHS U01 CA275301NIAID NIH HHS R01 AI130209NIAID NIH HHS R01 AI153506NIAID NIH HHS R01 AI153508NIAID NIH HHS R01 AI155086NIAID NIH HHS R01 AI164709NIA NIH HHS R01 AG030209NIDCR NIH HHS R01 DE017336
6 · The paper itself

Abstract

Epstein-Barr virus associated gastric cancer (EBVaGC) accounts for ~9-10% of gastric cancers worldwide and is defined by a distinctive molecular profile, including extreme hypermethylation of the DNA. Targeting this aberrant methylation may be a potential therapeutic strategy. EBV

Identifiers

PMID41280003
PMCPMC12632947

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.